LANCL1: A Potential Drug Target for Immune and Inflammatory Diseases

Target Name: LANCL1

NCBI ID: G10314

LANCL1

LANCL1: A Potential Drug Target for Immune and Inflammatory Diseases

Glutathione S-transferase 1 (LANCL1) is a gene that encodes a protein involved in the immune response and inflammation. The protein produced by LANCL1 is a key regulator of the immune response, and it has been shown to play a crucial role in the regulation of inflammation and tissue repair. Unfortunately, LANCL1 has also been implicated in the development of certain diseases, including systemic lupus erythematosus and other autoimmune disorders.

The aim of this article is to provide an overview of LANCL1, including its function, the potential uses of LANCL1 as a drug target, and the current research into LANCL1-related diseases.

Function of LANCL1

LANCL1 is a member of the superfamily of NAD+-dependent enzymes, also known as transferases. These enzymes use NAD+ as a cofactor to transfer a phosphate group to other molecules, and they are involved in a wide range of cellular processes, including metabolism, redox reactions, and signaling pathways.

LANCL1 is primarily expressed in the liver, and it has been shown to play a key role in the regulation of the immune response. In particular, LANCL1 is involved in the detoxification of toxic substances and in the regulation of inflammation.

LANCL1 has also been shown to play a role in the regulation of cell cycle progression, and it has been shown to interact with the protein p21 (CKAP2). p21 is a negative regulator of the G1-phase of the cell cycle, and it has been shown to play a role in the regulation of cell cycle progression, cell survival, and the transition from the G1 to the S phase of the cell cycle.

Potential uses of LANCL1 as a drug target

The potential uses of LANCL1 as a drug target are numerous. As mentioned above, LANCL1 is involved in the regulation of the immune response, and it has been shown to play a key role in the regulation of inflammation. Therefore,LANCL1 may be a useful target for the treatment of autoimmune disorders such as systemic lupus erythematosus.

LANCL1 may also be a useful target for the treatment of certain types of cancer. For example, LANCL1 has been shown to be involved in the regulation of cell cycle progression, and it has been shown to interact with the protein p21 (CKAP2). Therefore,LANCL1 may be a useful target for the treatment of cancer by inhibiting the activity of LANCL1 and p21.

Current research on LANCL1-related diseases

The current research on LANCL1-related diseases is focused on the understanding of its functions and the development of new treatments. One of the main areas of research is the study of the mechanisms of action ofLANCL1, including its role in the regulation of the immune response and inflammation.

Another area of research is the study of the potential uses of LANCL1 as a drug target. Researchers are working to develop new treatments for LANCL1-related diseases, including the treatment of autoimmune disorders and cancer.

Conclusion

LANCL1 is a protein involved in the immune response and inflammation that has been implicated in the development of certain diseases. The potential uses of LANCL1 as a drug target are numerous, including the treatment of autoimmune disorders and cancer. The current research on LANCL1-related diseases is focused on understanding its functions and developing new treatments.

Protein Name: LanC Like Glutathione S-transferase 1

Functions: Functions as glutathione transferase. Catalyzes conjugation of the glutathione (GSH) to artificial substrates 1-chloro-2,4-dinitrobenzene (CDNB) and p-nitrophenyl acetate. Mitigates neuronal oxidative stress during normal postnatal development and in response to oxidative stresses probably through GSH antioxidant defense mechanism (By similarity). May play a role in EPS8 signaling. Binds glutathione (PubMed:19528316)

The "LANCL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LANCL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets